A recent study conducted by Mark Purdue, PhD, and his international research team identified new susceptibility regions that are associated with the risk of developing renal cell carcinoma (RCC). A previous genome-wide association study (GWAS) identified 13 regions of the genome associated with RCC risk, but the study only analyzed patients with European ancestry and did not utilize a diverse population. ...
Renal Cell Carcinoma Diagnostics
Advertisement
We spoke with several researchers involved in exploring the clinical utility of liquid biopsy for genitourinary cancers.
Dr. Wei helped uncover genetic, transcriptional, and immune differences in TFE3-rearranged RCC versus papillary, ccRCC.
A new study on the prognostic value of perinephric fat, renal sinus fat, and renal vein invasion in patients with pT3a RCC.
Targeted gene panel testing can serve as an option for patients if syndromic features are present.
Researchers sought to identify the frequency of germline mutations in patients 46 years or younger.
Researchers evaluated biomarkers to determine their prognostic potential for determining treatment modality for ccRCC.
Patients with early-onset RCC underwent genetic testing more often than those with bilateral RCC.
A Merit Award-winning abstract offered insight into differences in RCC susceptibility and implications for genetic screening.
Certain risk factors can result in pathological upstaging in patients treated with nephrectomy for nonmetastatic RCC.
Dr. Calais describes a novel radiotracer and explains how the recent data on this radiotracer further support its use.
Advertisement
Video Insights
Conferene Coverage
Dr. Miles-Thomas shares the challenges of female urology and her vision for her tenure as AUA treasurer.
Dr. Afari elaborates on the factors he identified that contribute to renal function improvement post-partial nephrectomy.
Dr. Galsky shares the first OS data update on the CheckMate 274 trial, which he gave at the 2024 EAU Congress.
Dr. Julian Chavarriaga describes his study on using miRNA as a liquid biomarker to detect malignancy in testicular masses.
Dr. Finati discusses what the future has in store for further investigation utilizing larger patient databases.
Drs. Grasso and Verhovsky discuss the potential of endoscopic treatment with surveillance for patients with bladder cancer.
Advertisement
Section Editor
Daniel Joyce, MDDepartment of Urology | Vanderbilt University Medical Center
Advertisement
Get the latest RCC research straight to your inbox.
